SEHK:1801Biotechs
Innovent Biologics Cancer Updates Test Investor Confidence In Undervalued Shares
Innovent Biologics (SEHK:1801) has received Chinese regulatory approval for a combination of TYVYT® (sintilimab) and ELUNATE® (fruquintinib) to treat advanced renal cell carcinoma.
The company separately reported encouraging clinical data for its first in class PD-1/IL-2 bispecific fusion protein IBI363 in multiple hard to treat cancers, including lung and colorectal cancer.
At a current share price of HK$80.95, Innovent Biologics sits after a mixed shorter term share performance, with the...